Nanjing Legend/GenScript Bio and Cancer's Next Big Thing: CAR-T
It was a perfect underdog story: a small, little-known company, with no history of clinical success, wows the world's biggest cancer convention with breakthrough data. That's what China’s Nanjing Legend Biotech did at the most recent ASCO meeting. Legend's CAR-T candidate produced remission in 94% of multiple myeloma patients. Shortly later, Legend partnered the CAR-T drug with Janssen Pharma, which agreed to a $350 million upfront payment, plus milestones and a 50/50 split in costs and profits. But there are 186 CAR-T molecules in development in the US, and another 153 in China. Will Legend's 94% success rate -- astonishing as it seems -- be enough for best-in-class? More details....
Share this with colleagues:
Original Article: Nanjing Legend/GenScript Bio and Cancer's Next Big Thing: CAR-T
NEXT ARTICLE
More From BioPortfolio on "Nanjing Legend/GenScript Bio and Cancer's Next Big Thing: CAR-T"
